ArticleThe Eurasian journal of medicine2023
The Association of Plasma Osmolarity with No-Reflow in Patients with ST Elevation Myocardial Infarction: A Retrospective Cohort Study.
Article in The Eurasian journal of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In this study, we sought to examine the statistical association of plasma osmolarity with noreflow development in patients with ST-segment elevation myocardial infarction (STEMI) who were treated with primary percutaneous coronary intervention (pPCI). Methods: In this retrospective study, we included data from 1294 consecutive STEMI patients who have undergone pPCI. For each patient, we measured the plasma osmolarity using the following equation: 2 × sodium+0.9 glucose+0.93 × urea × 0.5. Results: Occurrence of angiographic no-reflow was 21.7% (n=281) in the study. The mean plasma osmolarity level was significantly higher in patients with no-reflow compared to those without no-reflow (300.6 ± 9.4 mOsmol/L versus 292.8 ± 10.5 mOsmol/L, P < .001, respectively). In multivariate logistic regression analysis, plasma osmolarity was found to be independently related to no-reflow development (odds ratio: 1.061; 95% CI, 1.045-1.076; P < .001). According to the receiver operating characteristic curve analysis, a plasma osmolarity level greater than 290.2 mOsmol/L was identified as the optimal value for predicting the occurrence of no-reflow. This cutoff demonstrated a sensitivity of 91.8% and a specificity of 45.8%. Conclusion: This is the first study to establish an independent relationship between higher plasma osmolarity and the development of no-reflow in patients with STEMI who have undergone pPCI. This finding suggests that plasma osmolarity may be a useful marker for the prediction of no-reflow in STEMI patients who have undergone pPCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.